A 69-year-old man developed a cough and fever during treatment with corticosteroid (P.O and external use) for erythroderma. Chest X-ray films revealed a consolidation shadow in the right upper lung field. Initial treatment with sulbactam sodium/ampicillin followed by imipenem/ cilastatin was not effective. A urinary antigen test for Legionella was positive, making for a diagnosis of Legionella pneumonia. Intravenous treatment with ciprofloxacin (CPFX) was remarkably effective. His symptoms, chest Xray and laboratory data rapidly improved after its initiation. Our findings strongly suggest that intravenous treatment with fluoroquinolones including CPFXshould also be a first choice for Legionella pneumoniain Japan.
Introduction
Because Legionella proliferates in living cells, pneumonia caused by this bacterium should be treated with an antimicrobial drug that exhibits good cellular distribution. Legionella pneumoniahas been treated with combinations of macrolides, tetracyclines (drip infusion or p.o.), rifampicin (RFP), and new quinolones (p.o.) (1) . In Western countries, drip infusion of azithromycin or someof the newquinolones is commonlyused to treat Legionella pneumonia, and the usefulness of this therapy has been established (2) . In Japan, only intravenous ciprofloxacin (CPFX), available on the market in November 2000, has been approved, and there are as yet few reports of Legionella pneumonia successfully treated with this drug. Weencountered a case of Legionella pneumonia which could be successfully treated with monotherapy with intravenous CPFX.
Case Report
A 69-year-old man visited our outpatient clinic with a high fever and a cough as the chief complaints. The patient had been treated with a corticosteroid (p.o., external use) for erythroderma since July 2001 at the Department of Dermatology of our hospital. On admission, a lobar pneumonia caused by pneumococci was suspected based on a consolidation shadowin the right upper lung field on chest X-ray films and gram-positive diplococci detected in the gram stain of sputum smear. The patient was administered sulbactam sodium/ampicillin (SBT/ABPC) at 6 g/day for 7 days. When his symptoms and chest X-ray findings rapidly improved, he was discharged. The patient again visited the dermatologic clinic in our hospital because of high fever and productive coughing that had again manifested from October 10. Recurrence of lobar pneumonia wassuspected based on a consolidation shadowat the same site as before on chest X-ray films. Administration of the same antibiotic combination, SBT/ABPC, at 6 g/day for 2 days was not effective for symptoms or chest X-ray findings. Treatment was then changed to imipenem/cilastatin (IPM/CS) at 1.5 g/ day, taking into consideration the possibility of resistant pneumococci. The symptomswere again not alleviated, and the consolidation shadow on chest X-ray films deteriorated. The patient was then referred to our department. The finding from physical examinations at the time of readministration were as follows; height: 157.9 cm, body weight: 56.0 kg, body temperature:
38.0°C, blood pressure: 132/80 mmHg,pulse rate: 72, regular, respiratory rate: 30. The palpebral conjunctivae were not anemic, and the bulbar conjunctivae were not icteric. There were no abnormal heart sounds, though coarse crackles were audible in the right upper lung field. There were no abnormalities in the abdomenand no pitting edema on the legs. Erythroderma with desquamation was noted all over the body. Laboratory values (Table 1) Figure 3 . Clinical course of the present case.
5.6 mg/dl and 2.6 mg/dl, respectively, and blood sugar 235 mg/dl and HbAlc 7.3% indicated an abnormality in glucose tolerance. On blood gas analysis, PaO2 (room air) was 78.0 Torr, suggesting mild hypoxemia. On chest roentgenogram ( Fig. 1) : A diffuse homogeneous shadow in the right upper field was noted but on air-bronchogram it was not obvious, at re-administration. An ipsilaterally dull costophrenic angle was noted.
Chest CT is shown in Fig. 2 ; A consolidation shadow on airbronchogram was noted in the right upper lobe (S2, S3). Effective pleural effusion was not noted on this CT, but the lower level of the CT revealed a slight pleural effusion. In the clinical course (Fig. 3) ; smear and culture of sputum yielded no significant findings, and testing for a urinary antigen to pneumococci (now Streptococcus pneumoniae; Binax, Inc., Portland, Maine, USA)was negative, though the test for a urinary antigen to Legionella pneumophila serogroup 1 (now Legionella' , Binax, Inc., Portland, Maine, USA) became positive; based on which Legionella pneumonia was then diagnosed, even through culture and PCRresults were negative. In addition, the findings including a high fever of 40°C, tachypnea of 30 times/min, a high CRP value (27.1 mg/dl), a shadow extended over 2/3 or more of the right lung on chest X-ray films, an age of 69 years, treatment with a steroid and complication by diabetes mellitus supported the diagnosis of severe Legionella pneumonia. The antibiotics were then changed to a monotherapy of intravenous ciprofloxacin (CPFX: 600 mg/day) because of its excellent activity against bacterium and a good penetration to phagocytic cells. Body temperature fell the next day, cough subsided 7 days after the start of administration, inflammatory response and blood gas findings were normalized, and the consolidation shadow on chest X-ray films disappeared (Fig. 4) ; treatment was then switched to oral administration of levofloxacin (400 mg/day). The patient made favorable progress after this change of treatment, and was discharged Legionella Pneumonia Successfully Treated with CPFX after 3 days of oral administration of levofloxacin.
Discussion
Legionella is a cause of both community-acquired and nosocomial pneumonia, and has been reported to account for differing percentages of cases of community-acquired pneumonia in Western countries (3, 4) . Recent studies revealed that it accounted for 3 to 5% of community-acquired pneumonia in Japan (5) . Pneumonia caused by Legionella tends to manifest in patients with immunosuppression resulting from administration of a carcinostatic or a steroid (6), and becomessevere (7, 8) .
Because Legionella proliferates in phagocytes and produces p-lactamase, an antimicrobial drug with good distribution in phagocytic cells and resistance to P-lactamase-producing bacteria should be selected for treatment of Legionella-induced diseases.
It has recently been confirmed in basic and clinical studies that various fluoroquinolones and somenewmacrolides are effective against Legionella (9-1 1). Edelstein (1) 1, 12, 13 ). Among the guidelines for injection, only CPFXis available in Japan. CPFXhas a potent antimicrobial activity against Legionella pneumophila, with an MIC90 of 0.015 to 0.06 |ig/ml (14) . The concentration in lung tissue after EMadministration is 0.8±1.3 jig/ml but that after CPFXadministration reaches a muchhigher level at 4.713.1 jiig/ml (15) . An in-vitro study on the suppression of intracellular proliferation of Legionella and a study on treatment in a modelof Legionella pneumoniaalso revealed that CPFXis very effective (16) . In Western countries, CPFX has been used for more than 10 years for the treatment of Legionella pneumonia, and favorable therapeutic results have been obtained with it (17, 18) . The present case was judged to be severe pneumonia as the patient was old and had an underlying disease in addition to the high fever and high CRPvalue; based on the severity classification in the guidelines for diagnosis and treatment of community-acquired pneumonia proposed by the Japanese Respiratory Society. In Western countries, levofloxacin by injection is recommendedas the drug of first choice for treatment of severe pneumonia including Legionellosis (9) . The present case was treated by injection with CPFXand the treatment was successful; it could be completed in a short period of time with CPFXby injection for 7 days and oral LVFXfor 4 days. Okano et al reported a case of Legionellosis for which a combination of EMand CPFXwas successful (19) , however the present case could have been treated successfully with CPFXalone. Based on an aging population and increases in the numbers of immunosuppressed patients, and also on the technological improvements in the identification of causative microorganisms of pneumonia, cases of Legionella pneumoniacan be expected to increase. At the time of diagnosis, Legionella pneumonia is severe in most cases; in such cases good therapeutic effects as noted with fluoroquinolones cannot be expected with conventional therapeutics. As shown in previous Western reports, intravenous injection of CPFXis excellent for the treatment of Legionella pneumonia. In the present case as well, the usefulness of CPFXwas demonstrated suggesting that monotherapy with intravenous injection of CPFXis effective for Legionella. The effectiveness of the treatment with intravenous injections of CPFXin cases of Legionella pneumonia including the severe cases need further study. It is hoped that new fluoroquinolones for injection will be developed.
